Disclosed is a pharmaceutical composition for treating presbyopia including a cholinesterase inhibitor in a therapeutically effective amount for treating presbyopia. Additionally, the pharmaceutical composition further includes an acetylcholinesterase inhibitor in a therapeutically effective amount for treating presbyopia. A method for treating presbyopia is also disclosed, including the following steps: administering a pharmaceutical composition including a cholinesterase inhibitor or a combination of a cholinesterase inhibitor and an acetylcholinesterase inhibitor to a patient in need thereof; and simultaneously detecting changes in reading distance (UNVA40) and computer screen usage distance (UNVA66) of the patient.

This disclosure relates to methods of treating a coronavirus infection or other microbial infection comprising administering an effective amount of a plant extract, or compound, or combination of compounds derived therefrom to a subject in need thereof. In certain embodiments, the plant extract is obtained by a process of contacting a segment of a plant a with a solvent providing an extract as reported herein. In certain embodiments, this disclosure contemplates pharmaceutical compositions comprising extracts and components contained therein for use in methods of treating viral or other microbial infections.

This disclosure relates to methods of treating a coronavirus infection or other microbial infection comprising administering an effective amount of a plant extract, or compound, or combination of compounds derived therefrom to a subject in need thereof. In certain embodiments, the plant extract is obtained by a process of contacting a segment of a plant a with a solvent providing an extract as reported herein. In certain embodiments, this disclosure contemplates pharmaceutical compositions comprising extracts and components contained therein for use in methods of treating viral or other microbial infections.

Disclosed is a powdered plant preparation and a method for its preparation, as well as microgranules and tablets obtained therefrom, and methods for their preparation. The invention is suitable for use in the production of herbal preparations.

Disclosed is a powdered plant preparation and a method for its preparation, as well as microgranules and tablets obtained therefrom, and methods for their preparation. The invention is suitable for use in the production of herbal preparations.

A composition includes the following active components: component (1): at least one selected from the group consisting of Ligustrum fruit, yerbadetajo herb, Lilium bulb, Polygonatum Rhizome, Lycium fruit, Sesamum indicum, and black soybean; component (2): at least one selected from the group consisting of Suberect spatholobus stem, Longan aril, wild turmeric, zedoary root, Luffa vegetable sponge, Sparganium rhizome, safflower, Artemisia anomala, common fenugreek seed, Dipsacus japonicus root, Drynaria herb, sea horse, Cynomorium herb, and Astragalus Seed; component (3): at least one selected from the group consisting of tea leaf, plantago seed, plantago herb, coix seed, small red-bean, corn silk, Lophatherum herb, Benincasa seed, mallow seed, knotgrass, and Lygodium spore; and component (4): at least one selected from the group consisting of Dioscorea japonica Thunberg, Eleutherococcus senticosus Rhizome, honey, oriental bush cherry, ginger root, ripe tangerine peel, unripe tangerine peel, immature orange, malt starch syrup, jujube fruit, and non-glutinous rice.

This invention discloses a herbal composition for treating or preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including the wild type and its different variant strains. The composition comprises the extract of Platycodon grandiflorum, which showed the synergistic inhibitory effect of infection compared to the Anti-epidemic No. 1 (AN1) consisted of Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, Atractylodes lancea, Pogostemon cablin, Glehnia littoralis, Lonicera japonica and Cyrtomium fortunei.

This invention discloses a herbal composition for treating or preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including the wild type and its different variant strains. The composition comprises the extract of Platycodon grandiflorum, which showed the synergistic inhibitory effect of infection compared to the Anti-epidemic No. 1 (AN1) consisted of Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, Atractylodes lancea, Pogostemon cablin, Glehnia littoralis, Lonicera japonica and Cyrtomium fortunei.

This invention discloses a herbal composition for treating or preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including the wild type and its different variant strains. The composition comprises the extract of Platycodon grandiflorum, which showed the synergistic inhibitory effect of infection compared to the Anti-epidemic No. 1 (AN1) consisted of Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, Atractylodes lancea, Pogostemon cablin, Glehnia littoralis, Lonicera japonica and Cyrtomium fortunei.

Association comprising or consisting of a dry extract of Polypodium leucotomos and a dry extract of Larixdecidua bark for use in the prevention of damage from exposure to UVA, UVB, UVC and/or IR rays and relative oral nutraceutical or pharmaceutical compositions.